See more : Shanghai Liangxin Electrical Co.,LTD. (002706.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Quality Houses Hotel and Residence Freehold and Leasehold Property Fund (QHHR.BK) Income Statement Analysis – Financial Results
- Hebei Construction Group Corporation Limited (1727.HK) Income Statement Analysis – Financial Results
- HumanCo Acquisition Corp. (HMCO) Income Statement Analysis – Financial Results
- Garnet International Limited (GARNETINT.BO) Income Statement Analysis – Financial Results
- Evergreen Aviation Technologies Corporation (2645.TW) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
Corgenix to Host Conference Call to Discuss Third Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, May 15, 2014, at 4:00 p.m. EDT to discuss the Company’s financial and operating performance for its quarter...
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
DENVER--(BUSINESS WIRE)--A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each...
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
DENVER--(BUSINESS WIRE)--An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked...
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company’s Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others,...
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues and net income increased both...
Corgenix to Host Conference Call to Discuss Second Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its quarter...
Corgenix to Host Conference Call to Discuss Second Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its quarter...
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio™ Assay
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and...
Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting
DENVER & NEW ORLEANS--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the...
Corgenix Inks Collaborative Diagnostic Test Development Deal with Zalgen Labs
DENVER & GERMANTOWN, Md.--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Zalgen Labs, a biotechnology company dedicated to the development of...
Source: https://incomestatements.info
Category: Stock Reports